110 related articles for article (PubMed ID: 35724566)
1. Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
Bai JF; Majjigapu SR; Sordat B; Poty S; Vogel P; Elías-Rodríguez P; Moreno-Vargas AJ; Carmona AT; Caffa I; Ghanem M; Khalifa A; Monacelli F; Cea M; Robina I; Gajate C; Mollinedo F; Bellotti A; Nahimana A; Duchosal M; Nencioni A
Eur J Med Chem; 2022 Sep; 239():114504. PubMed ID: 35724566
[TBL] [Abstract][Full Text] [Related]
2. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage.
Galli U; Ercolano E; Carraro L; Blasi Roman CR; Sorba G; Canonico PL; Genazzani AA; Tron GC; Billington RA
ChemMedChem; 2008 May; 3(5):771-9. PubMed ID: 18247435
[TBL] [Abstract][Full Text] [Related]
4. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure-based comparison of two NAMPT inhibitors.
Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
[TBL] [Abstract][Full Text] [Related]
7. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Fratta S; Biniecka P; Moreno-Vargas AJ; Carmona AT; Nahimana A; Duchosal MA; Piacente F; Bruzzone S; Caffa I; Nencioni A; Robina I
Eur J Med Chem; 2023 Mar; 250():115170. PubMed ID: 36787658
[TBL] [Abstract][Full Text] [Related]
9. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
10. The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression.
Sauer H; Kampmann H; Khosravi F; Sharifpanah F; Wartenberg M
Clin Exp Pharmacol Physiol; 2021 Mar; 48(3):422-434. PubMed ID: 33349973
[TBL] [Abstract][Full Text] [Related]
11. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Hasmann M; Schemainda I
Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
[TBL] [Abstract][Full Text] [Related]
12. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
[TBL] [Abstract][Full Text] [Related]
13. Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Zhang K; Ni Y; Chen J; Tu Z; Wu X; Chen D; Yao H; Jiang S
Bioorg Med Chem Lett; 2019 Jun; 29(12):1502-1506. PubMed ID: 30992165
[TBL] [Abstract][Full Text] [Related]
14. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
[TBL] [Abstract][Full Text] [Related]
15. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
16. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor.
Kang GB; Bae MH; Kim MK; Im I; Kim YC; Eom SH
Mol Cells; 2009 Jun; 27(6):667-71. PubMed ID: 19533035
[TBL] [Abstract][Full Text] [Related]
19. New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents.
Conforti I; Benzi A; Caffa I; Bruzzone S; Nencioni A; Marra A
Med Chem; 2024 Feb; ():. PubMed ID: 38333979
[TBL] [Abstract][Full Text] [Related]
20. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
